Published in Blood Weekly, May 11th, 2006
"Our aim was to evaluate the efficacy and safety of adding adefovir to lamivudine therapy for HBV-infected patients resistant to lamivudine," wrote J.B. Gornals and colleagues, University of Barcelona.
"Among 17 studied patients, 7 had chronic active HBV infection and 10 were posttransplant with HBV infection (9 with de novo HBV). They received lamivudine plus adefovir therapy for 2 years."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.